Introduction
Chemokines can modulate cancer cell growth since many types of cancer cells express chemokines and chemokine receptors (1) . Several accumulating evidences have indicated that the chemokine (C-C motif) ligand 5 (CCL5) and C-C chemokine receptor 5 (CCR5) may be significantly involved in the development of melanoma (2) , hepatoma (3), glioblastoma, Hodgkin lymphoma (4), oral, prostate, colorectal (5), cancer (6) and breast cancer cells (7) . Meanwhile, CCR5 disruption and inhibitors have been demonstrated to inhibit experimental tumor growth and metastasis of pancreatic cancer (8, 9) , prostate cancer (10) and breast cancer (4) . We have provided direct evidence by showing that CCR5 knockout (CCR5 −/− ) mice have a lung-tumor-growth inhibitory effect in a xenograft model (11) . However, the tumor-suppressive effects and action mechanisms of CCR5 in the carcinogen-induced tumor growth model has been not reported.
CCR5 increases tumor growth by the inhibition of antitumor activity of immune cells and macrophages (10) . It was found that a CCR5 inhibitor (TAK-779) reduced regulatory T cells migration to tumors so that tumor growth was smaller than in non-treated control mice (9) . Phagocytosis of apoptotic/necrotic tumor cells resulted in maturation of Dentritic cells (DCs) with downregulated expression of the C-C chemokine receptors CCR2 and CCR5 (12) . It was also reported that a CCL5-dependent mechanism of transferring immunity from exogenously activated CD4(+) T cells to tumor-exposed host cells resulted in sustained antitumor effects (13) . CCR5 boosts T-cell responses to tumors by modulating helper-dependent CD8(+) T-cell activation (14) . Similar to this finding, we found that the CCR5 +/+ mice injected with melanoma cells apparently have a lower number of cytotoxic T cells and natural killer(s), as well as dendritic cells in spleen tissues compared with those of CCR5 −/− mice. These data suggest that changes of tumor-associated cytotoxic lymphocytes could play an important role in CCR5-mediated tumor growth.
Regulation of CCR-mediated tumor growth and metastasis is associated with activation of nuclear factor-kappaB (NF-κB). An increase of CCL5-mediated oral cancer motility (5) and lung metastasis is correlated with the activation of NF-κB (15) . Inhibition of NF-κB by dehydroxymethyl-epoxyquinomicin induces cell death of primary effusion lymphoma through the inhibition of CCR5 expression (16) . Thus, CCR5-mediated tumor development is possibly associated with the activation of NF-κB. NF-κB plays a crucial role in the suppression of apoptosis, induction of cell proliferation and inflammation, and is closely associated with cancer development (17) . Constitutive activation of NF-κB has been described in a great number of cancers including colon, prostate and lung cancers (18) (19) (20) and was found to upregulate anti-apoptotic genes and/or downregulate apoptotic gene expression (21) . NF-κB is also essential for interleukin (IL)-2, IL-3, Granulocyte macropharge colony-stimulating factor (GM-CSF) and interferon γ expressions in T lymphocytes (22) (23) (24) (25) (26) . NF-κB-deficient mice cause a tissue-specific deficiency of various cytokines and growth factors in T cells and macrophages affecting both innate and humoral immune responses in the host (27, 28) . Therefore, NF-κB can act as a tumor-growth modulator either by directly affecting apoptotic cancer cell death by stimulating tumor-killing lymphocytes infiltration or by increasing the production of tumor-killing lymphokines. Thus, it is possible that CCR5 promotes tumor growth through the activation of NF-κB, which activates or recruits lymphocytes via regulation of cytokines, facilitating tumor growth. To test this hypothesis, we compared tumor growth patterns, activity of NF-κB and levels of cytokines, as well as lymphocytes in carcinogen-induced lung tumors in CCR5 +/+ and CCR5 −/− mice.
mice were housed and bred under specific pathogen-free conditions at the Laboratory Animal Research Center of Chungbuk National University, Korea. The mice (n = 4/cage) were maintained in a room with a constant temperature of 22 ± 1°C, relative humidity of 55 ± 10% and 12-h light/dark cycle, and fed standard rodent chow (Samyang, Korea) and purified tap water ad libitum. The CCR5 +/+ mice (n = 20) and CCR5 −/− mice (n = 20) matched by age (10-11 weeks old) and weight (16-19 g ) were used. Control mice (B6129PF2/J) were F2 hybrid mice from the C57BL/6J-AW-J and 129P3/J parental strains. CCR5 mice (B6, 129P2-Ccr5tm1Kuz/J) have the entire coding region of the CCR5 gene deleted from the parental strains, B6;129P2-Ccr5tm1Kuz and B6;129P2-Cmkbr5tm1Kuz. These mice received a single intraperitoneal injection of urethane (1 g/kg in 100 µl saline) or saline control (100 µl) on experimental day 0. Mice were killed after 4 months. Primary endpoints of carcinogenesis were number, size and histologic type of lung neoplastic lesions (atypical alveolar hyperplasia versus adenoma and adenocarcinoma).
Cell culture and in vitro treatment
NCI-H460 and A549 human lung cancer cells were obtained from the American Type Culture Collection (Manassas, VA, USA). RPMI1640, penicillin, streptomycin and fetal bovine serum were purchased from Invitrogen (Carlsbad, CA, USA). NCI-H460 and A549 human lung cancer cells were grown in RPMI1640 with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in 5% CO 2 humidified air.
Cell viability assay
To determine the cell number, cultured cells were trypsinized with TrypLE Express (Invitrogen) and then the cells were pelleted by centrifugation for 5 min at 1500 rpm. Cells were resuspended in 10 ml of phosphate-buffered saline (PBS) and 0.1 ml of 0.2% trypan blue was added to the cancer cell suspension. Subsequently, a drop of suspension was placed into a Neubauer chamber and the living cancer cells were counted. Cells that showed signs of staining were considered to be dead, whereas those that excluded trypan blue were considered viable. Each assay was carried out in triplicate.
Western blotting
Lung tissues were homogenized with protein extraction solution (PRO-PREPTM, Intron Biotechnology, Seoul, Korea) and lysed by 60 min incubation on ice. The tissue lysate centrifuged at 15 000 r.p.m. for 15 min at 4°C. Equal amount of proteins (40 µg) were separated on a sodium dodecyl sulfate/12% polyacrylamide gel and then transferred to a polyvinylidene difluoride membrane (GE Water and Process technologies, Trevose, PA, USA). Blots were blocked for 1 h at room temperature with 5% (w/v) non-fat dried milk in TrisBuffered Saline Tween-20 [10 mM Tris (pH 8.0) and 150 mM NaCl solution containing 0.05% Tween -20] . After a short washing in Tris-Buffered Saline Tween-20, the membranes were immunoblotted with the following primary antibodies: mouse monoclonal antibodies directed against p65 and p50 (1:500 dilutions; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal antibodies directed against Bax and PARP (1:500 dilutions; Santa Cruz Biotechnology) and against caspase-3, caspase-9, Bcl-2 and cIAP-1 (1:1000 dilutions; Cell Signaling Technology, Beverly, MA). The blots were incubated with the respective horseradish peroxidase-conjugated antirabbit or antimouse IgG (1:4000 dilutions; Santa Cruz Biotechnology). Immunoreactive proteins were detected with the enhanced chemiluminescence detection system.
Immunohistochemistry
All specimens were fixed in formalin and embedded in paraffin for examination. Sections (4-µm thickness) were stained with hematoxylin and eosin (H&E) and analyzed by immunohistochemistry. The paraffin-embedded sections were deparaffinized and rehydrated, washed in distilled water and then subjected to heat-mediated antigen retrieval. Endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide in methanol for 15 min, in blocking serum for 4 h at room temperature. Thereafter, the slides were washed three times for 5 min each in PBS and incubated with biotinylated antimouse and antirabbit antibodies for 2 h. The slides were washed in PBS, followed by the addition of avidin biotin peroxidase complex (ABC kit; Vector Laboratories, Burlingame, CA, USA). The slides were washed and the peroxidase reaction was developed with diaminobenzidine and peroxide, followed by counterstaining with hematoxylin, mounting in aqua-mount and evaluation under a light microscope (magnification ×200; Olympus, Tokyo, Japan). A negative control was included in all experiments by omitting the primary antibody. For the detection of apoptotic cell death in the tumor tissues, the paraffin-embedded sections were incubated in a mixture of the labeling solution (540 µl) and enzyme solution (60 µl) for 1 h at 37°C and then washed three times in 0.1 M PBS for 5 min each, according to the manufacturer's instructions. Next, the sections were incubated with 4′,6-diamidino-2-phenylindole for 15 min at 37°C. Finally, the sections were rinsed, mounted on slides and coverslipped for fluorescence microscopy (DAS microscope).
Gel electromobility shift assay
A gel electromobility shift assay (EMSA) was performed according to the manufacturer's recommendations (Promega, Madison, WI). Briefly, the tumor tissues were homogenized in 200 µl of solution A (10 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid [pH 7.9], 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonylfluoride), vortexed vigorously, incubated on ice for 10 min and then centrifuged at 15 000 rpm for 15 min. The pelleted nuclei were resuspended in solution C (solution A supplemented with 420 mM NaCl and 20% glycerol) and incubated on ice for 20 min. The resuspended pellet was centrifuged at 15 000 r.p.m. for 15 min, and the resulting nuclear extract supernatant was collected in a chilled Eppendorf tube. Consensus oligonucleotides for IκB and STAT3 were end-labeled using T4 polynucleotide kinase and [P 32 ]-adenosine triphosphate for 10 min at 37°C. The gel shift reactions were assembled and incubated at room temperature. Subsequently, 1 ml of gel loading buffer was added to each reaction and loaded onto a 6% non-denaturating gel. The gel was subjected to electrophoresis until the dye was four-fifths of the way down the gel. The gel was dried at 80°C for 1 h and exposed to film overnight at −70°C.
Fluorescence-activated cell-sorting analysis for immune cell populations
Immune cell populations in the whole blood and spleen were analyzed using fluorescence-activated cell sorting (FACS). 100 µl of whole blood was collected using a hematocrit capillary tube and blocked with Fc-block (eBioscience, San Diego, CA, USA) to reduce non-specific antibody binding for 3 min at room temperature. Cells were then incubated in the dark with 10 µl of the appropriate fluorochrome-conjugated antibodies from eBioscience-T cells (anti-CD3-fluorescein isothiocyanate, 1:25), B cells (anti-CD19-PE, 1:25), NK cells (anti-CD49-APC, 1:50) for 20 min at 4°C. Cells were washed with 500 µl of FACS buffer containing 0.02% sodium azide and 2% fetal bovine serum in PBS. The red blood cells were lysed for 5 min with FACS lysis buffer (BD Bioscience, Franklin Lakes, NJ, USA) at room temperature, then re-washed with FACS buffer. Finally, each sample was fixed with 1% paraformaldehyde until further analysis. Flow cytometry was performed on the FACSCalibur system (BD Biosciences, Franklin Lakes, NJ, USA). Control samples were matched for each fluorochrome. Data were analyzed using CellQuest software (Becton Dickinson, Franklin Lakes, NJ, USA). For immune cell population analysis in the spleens, tissues were disrupted by forcing them through 70-µm cell strainer into 10 ml of cold PBS using a rubber-tipped syringe plunger. The cell suspensions were then centrifuged at 1500 r.p.m. for 10 min and the supernatants were discarded. The cells were resuspended in 3 ml ACK lysing buffer (LONZA, Walkersville, MD) for 3 min and the debris was sedimented by centrifuging at 1500 r.p.m. for 10 min. Cell concentrations were determined by haemocytometer counting using trypan blue dye exclusion and were adjusted to 1 × 10 6 cells/ml. Single-cell suspensions were stained with the following fluorochrome-conjugated antibodies from BD Biosciences: B cells (anti-B220-APC, 1:100), T cells (anti-CD3-FITC, 1:400), NK cells (anti-CD49-APC, 1:50) and cytotoxic T cells (anti-CD8-FITC, 1:100). Flow cytometry and data analysis were done as mentioned above in blood.
Protein immuno-arrays
The tumor and spleen tissues were excised and homogenized in PBS with protease inhibitor cocktail (Sigma-Aldrich, USA) and Triton X-100 (final concentration 1%). The samples were frozen at −70°C, thawed and centrifuged at 10 000g for 5 min to remove any cellular debris. The tissue lysates were performed protein assay in the same way as for western blotting. About 300 µg of proteins collected from three samples per group was used for mouse cytokine array according to the protocol provided by supplier (Proteome Profiler™, #ARY006, R&D Systems, USA).
MCP-1 assay
To assay Brain derived neurotropic factor (BDNF) release in a cultured medium, we used a specific ELISA kit (R&D Systems, Minneapolis, MN, USA). In brief, cell-culture medium was collected 7 days after treatment with 4-o-methylhonokiol. To remove particulate, the medium was centrifuged at 15 000 r.p.m. for 5 min. Fifty micro liters of collected medium was added to BDNF antibody-coated 96-well plates and then incubated for 1 h at room temperature. After incubation, 100 µl of labeled antibody was added to each well, and the mixture was incubated for 1 h at room temperature. After washing the well with washing buffer (from the kit), substrate (200 µl) was added, and Deficiency of CCR 5 prevents tumor development the plate was incubated for 30 min at room temperature in the dark. Finally, the resulting color was assayed at 450 nm using a microplate absorbance reader within 30 min after the addition of stop solution. The amount of BDNF was expressed as nanogram per ml. All controls and samples were run in triplicate.
Statistical analysis
The data were analyzed using the GraphPad Prism 4 ver. 4.03 software (GraphPad Software, La Jolla, CA). Data are presented as mean ± standard deviation. Difference between CCR5 −/− mice and CCR5 +/+ mice were compared using a t-test. A value of P < 0.05 was considered to be statistically significant.
Results

Inhibition of tumor development in CCR5
−/− mice We treated mice with urethane, an environmental carcinogen that induces lung adenomas and compared the adenoma development in CCR5 +/+ and CCR5 −/− mice. The results revealed that CCR5 +/+ mice were more sensitive to urethane than CCR5 −/− mice. Sixteen weeks after urethane treatment (1 g per kg body weight), 100% (20/20) of the CCR5 +/+ mice developed adenomas, compared with only 35% (7/20) of the CCR5 −/− mice. The average number of urethane-induced adenomas per animal was about 13 and 27 in CCR5 +/+ mice (more than 1 mm in size), but about 9 and 8 (less than 1 mm in size), respectively, in CCR5 −/− mice ( Figure 1A ). Histopathological observation showed large-sized and more advanced tumors in the CCR5 +/+ mice. All lung tumors in urethane-treated CCR5 +/+ mice were adenomas, whereas ~40% of tumors in the CCR5 −/− mice were adenomas ( Figure 1B ). These data indicate that the development of lung adenocarcinomas in CCR5 −/− mice is reduced by both limiting the tumor size and delaying or preventing the conversion from adenoma to adenocarcinoma. The immunohistochemical analysis of the tumor sections, stained with H&E and for proliferation antigen Ki-67, revealed greater inhibition of tumor cell growth in CCR5 −/− mice tumors. The Ki-67 reactive cells were significantly reduced in CCR5 −/− mice ( Figure 1C) .
Decrease of NF-κB activity in tumor tissue of CCR5 −/− mice The activation of NF-κB plays a critical role in lung cancer cell survival and in CCR5 expression. To evaluate whether the tumor development inhibition was related with the inactivation of NF-κB in the urethane-treated lung, the DNA-binding activity of NF-κB was determined by an EMSA in the lung tissue. Higher DNA-binding activity was found in the lung tissues of CCR5 +/+ mice compared with that of CCR5 −/− mice ( Figure 2A) . Moreover, inhibition of the translocation of p50 and p65 into the nucleus through the inhibition of phosphorylation of IκB was also observed in CCR5 −/− mice lung tissues ( Figure 2B ). Immunohistochemistry analysis also confirmed that the intensity of nuclear staining for p65 was decreased in the lung tissues of CCR5 −/− mice ( Figure 2C ). 
Induction of apoptotic cell death and inhibition of the expression of anti-apoptotic proteins in CCR5
−/− mice To see whether inhibition of NF-κB activity results in the induction of apoptotic cell death and the expression of NF-κB target apoptotic cell-death regulatory protein, as well as the reduction of STAT3, a cell-death-regulating transcription factor reciprocally regulated by NF-κB, the levels of apoptotic cell death and expression of apoptotic cell-death regulatory proteins were assessed. Apoptotic cell death in lung sections was evaluated in the CCR5 +/+ and CCR5 −/− mice lung tissues. Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling revealed a higher frequency of apoptotic cell death in the lung tissues of the CCR5 −/− mice than that of the CCR5 +/+ mice ( Figure 3A) . Western blotting showed that higher levels of cleaved caspase-3, p53 and Bax, but lower levels of anti-apoptotic proteins, Bcl-2 and cIAP were found in the lungs of CCR5 −/− mice than in the CCR5 +/+ mice ( Figure 3B ). STAT3 is also significant in tumor growth, and NF-κB is reciprocally regulated by STAT3; thus, we also determined the activation of STAT3. We found that DNA-binding activity was decreased and agreed to the decreased DNA-binding activity (29, 30) , phosphorylation of STAT3 was also concomitantly and significantly lower in the CCR5 −/− mice lung tissues ( Figure 3C ).
Downregulation of MCP-1 in the lung and blood of CCR5
−/− mice To investigate the differential cytokine levels between CCR5 +/+ and CCR5 −/− mice lungs and blood, we conducted a cytokine array assay using a Mouse Proteome Array. Among 40 tested cytokines, levels of C5a, TIMP-1 and TREM-1 were increased about 2-fold, but MCP-1 was decreased about 6-fold, in the lungs of CCR5 −/− mice compared with those in CCR5 +/+ mice. Using this technique, no other cytokines were found to be different between CCR5 −/− and CCR5 +/+ mice lungs ( Figure 4B ). A different altered cytokine level was found in the blood of CCR5 −/− mice ( Figure 4C ). The B-lymphocyte chemoattractant; Keratinocyte derived chemokine (BLC and KC) levels were increased 2-to 3-fold, but the G-CSF level was elevated 4-to 5-fold in CCR5 −/− mice. However, MCP-1 was decreased 3-fold. Since the MCP-1 level was most significantly reduced in the lungs and blood, the expression of MCP-1 in lung tissues were analyzed by western blotting. The expression of MCP-1 was downregulated in lung tissues of the CCR5 −/− mice ( Figure 5A ). The level of MCP-1 in the lungs and blood was determined again by enzyme-linked immunosorbent assay and found that the level was significantly reduced in the CCR5 −/− mice ( Figure 5A ).
MCP-1 reversed CCR5-mediated inhibition of lung cancer cell growth
To further study the involvement of MCP-1 in CCR5-mediated cancer cell growth inhibition, we treated CCR5 antagonist, 3,7-dracetyl-1,3,7-triaza-5-phosphabicydo[3,3,1]nonane (DAPTA) and siRNA of CCR5. DAPTA and siRNA of CCR5 inhibited lung cancer cell growth in both A549 and NCI-H460 cells; however, this inhibition was reversed by the employment of MCP-1 protein ( Figure 5B ), indicating that the disruption of CCR5 could inhibit lung cancer cells through downregulation of MCP-1 in A549 cells( Figure 5C ). 
Induction of CD8 T cells and dendritic-cell infiltration into spleen, blood and tumor tissues of CCR5 −/− mice
Discussion
In the present study, we found that urethane-induced lung tumor development was much lower in CCR5 −/− mice compared with that in CCR5 +/+ mice. The inhibition of tumor development in the CCR5 −/− mice was associated with the inhibition of constitutively activated NF-κB and with decreased expression of NF-κB target anti-apoptotic proteins, Bcl-2 and cIAP1, but with increased expression of pro-apoptotic proteins, cleaved caspase-3 and Bax. The number of cytotoxic CD8 + T cells and dendritic cells were increased in the lungs and spleens, as well as in the blood of the CCR5 −/− mice. The tumor growth inhibition was also related with downregulation of MCP-1. Moreover, CCR5 antagonist and siRNA of CCR5 inhibited lung cancer cell growth in both lung cancer cells; however, this inhibition was reversed by the employment of MCP-1 protein, indicating that the disruption of CCR5 could inhibit lung tumor development, and this effect was associated with the inhibition of constitutively activated NF-κB and downregulation of MCP-1, as well as increase of CD8+ and dendritic-cell infiltration into tumor tissues.
NF-κB induces the expression of a large array of inflammatory mediators and plays a role as a core transcription factor in diverse immune responses, and thus it is a major factor responsible for cytokine-associated tumor development or antitumor immunity. Many tumors, including lung tumor, have increased levels of NF-κB (31), which is probably acting as a survival factor for tumor growth. In the lung tissues of CCR5 −/− mice, the expression of cell-death NF-κB target genes (Bax, caspase-3) was significantly increased, but NF-κB DNA-binding activity and the expression of such as Bcl-2 and cIAP was significantly reduced. In addition, CCR5 −/− prevented the phosphorylation of IκB, accompanied with the inhibition of the p50 and p65 translocation into the nucleus. STAT3 is also significant in tumor growth by regulating apoptotic cell-death-related protein expression, and NF-κB reciprocally regulated STAT3 (32) . We found that DNA-binding activity and phosphorylation of STAT3 were also concomitantly and significantly lower in the CCR5 −/− mice lung tissues. Thus, the inhibitions of NF-κB activity and the expression of target genes are critical in the inhibition of tumor development in CCR5 −/− mice. NF-κB can also modulate tumor development not only by directly affecting apoptotic cancer cell death but also by increasing the production of tumor-killing lymphokines or by stimulating The expression of apoptotic proteins was detected by western blotting using specific antibodies; cleaved caspase-3, Bax, Bcl-2 and cIAP1 in the lung tissues. The β-actin protein was used as an internal control. Three experimental animal data were seen. (C) The DNA-binding activity of STAT3 was determined in the nuclear extracts of the CCR5 −/− mice and CCR5 +/+ mice lung tissues (containing tumor tissues) by EMSA described in Material and methods. Expression of pSTAT3 and STAT3 nuclear fraction determined by western blotting. Three experimental animal data were seen. Scale bar indicates 50 µm.
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tumor-killing lymphocyte infiltration. Activation of NF-κB could modulate maturation of cytotoxic T cells and dendritic cells, and pathogenesis (33) . It was also reported that NF-κB target protein Inhibitor of apoptosis (IAP) antagonists can augment human and mouse T-cell cytotoxic activity to cancer cells depending on the activation of NF-κB signaling (34). Lin et al. (35) reported that an immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-κB pathway. We previously found that inhibition of NF-κB in tumor tissue is associated with increased cytotoxic and dendritic lymphocytes in the cytokine IL-32γ-induced melanoma tumorgrowth inhibition (36) . It was also noteworthy that inhibition of NF-κB activity prevented NK cell depletion and thus increased antitumor activity by decreasing IL-6 production (37). We recently also found that melanoma growth was inhibited via increase of cytotoxic T cells and NK cell activation by inhibition of NF-κB in the melanoma xenografted CCR5 −/− mice. In the present study, we did not find any changes in the NK cells. We could not understand why NK cells were involved in the melanoma growth in the xenograft model but not in the carcinogen-induced tumor. During the killing of cancer cells, NK cells have to recognize target cells (cancer cells), which express major histocompatibility complex-1 molecules and activating receptor ligands on their surface (38) . In the xenograft model, we used a cancer cell line, which are already expressed MHC-1 and activating receptor ligands, whereas these receptors may not be expressed enough in the lung tissues treated with carcinogen urethane. Thus, NK cells may not be significant in the tumor-growth inhibition in carcinogen-induced tumor growth. Further study is necessary to clarify this issue. However, these data suggest that inhibition of NF-κB is also critical in the increase of infiltration (or activation) of cytotoxic lymphocytes to suppress tumor development in the CCR5 −/− mice. It is important to note that MCP-1 was downregulated in the lungs and blood of CCR5 −/− mice treated with urethane. MCP-1 expression is regulated by the activation of NF-κB in several cells. It is reported that thrombin induces MCP-1 expression, which is due to the activation of Rho-kinase and subsequent p38MAPK/NF-κB signaling pathway in vascular endothelial cells (39) . Mou et al. (40) also reported that transforming growth factor-β1 modulates lipopolysaccharide-induced cytokine/chemokine production and inhibits NF-κB, extracellular signal-regulated kinases and p38 activation in dendritic cells in mice. Staphylococcus aureus regulates secretion of IL-6 and MCP-1 through the activation of NF-κB signaling pathway in human osteoblasts (41) . Immunoglobulin light chains activate NF-κB in renal epithelial cells through a Srcdependent mechanism in the production of MCP-1 (40). MCP-1 
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upregulates amylin expression in murine pancreatic β cells through ERK/JNK-AP1 and NF-κB-related signaling pathways (43) . These data supported that downregulation of MCP-1 in CCR5 −/− mice is due to the inactivation of NF-κB. MCP-1 is well known to stimulate tumor development. In patients with non-small-cell lung cancer, high MCP-1 levels in lipopolysaccharide-stimulated peripheral monocytes were found (44) . Activation of K-ras in the lung induces the elaboration of inflammatory chemokines, such as MCP-1, and promotes tumor progression (45) . It was also reported that an MCP-1 blockade, using an antibody of MCP-1, inhibits lung cancer tumor growth in animal models of non-small-cell lung cancer (46, 47) . Nutlin-3, a small molecule of Mdm 2 antagonist inhibits lung tumor by suppression of MCP-1 expression (48). Tang et al. (49) recently also reported that MCP-1 increases matrix metalloproteinase-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. These data have clearly demonstrated that downregulation of MCP-1 is associated with the inactivation of NF-κB and lung tumor regression in the urethane-induced lung tumor development in the CCR5 −/− mice. It is noteworthy that altering macrophage phenotype and activating CD8+ cells were contributed for MCP-1 blockade-induced lung tumor-growth inhibition in animal models of non-small-cell lung cancer (46, 47) . It is found that disruption of CCR5/CCL5 signaling by systemic administration of a CCR5 inhibitor (TAK-779) reduced regulatory T cells migration to tumors so that tumors are smaller than in control mice (50) . Similar to this finding, we found that the CCR5 +/+ mice treated with urethane apparently have a lower number of cytotoxic T cells (CD8+ T lymphocyte cells) and dendrite cells in the spleen and lung tissues, as well as in the blood compared with those of CCR5 −/− mice. Taken all together, it is possible that relatively increased tumor-associated cytotoxic lymphocytes could play an important role in inhibiting tumor growth in the urethanetreated CCR5 −/− mice through the downregulation of MCP-1. It is also true that changing other cytokines such as G-CSF in CCR5 −/− mice could be important. G-CSF level in the blood is significantly elevated. G-CSF can be used as a prognostic biomarker in non-small-cell lung cancer (51) . It was recently reported that elevated G-CSF levels in the blood of lung tumor patients were decreased by the surgical removal of the tumor (52) . G-CSF could play a role in the production and maintenance of specific tumorassociated macrophages in solid tumors, a subclass of marrowderived macrophages present in surrounding tumor tissue and appear to correlate with the prognosis and sensitivity to chemotherapy (53) . GM-CSF can induce Bcl-2 and NF-κB activation in hematopoietic cell survival (54) . Thus, other cytokine (such as G-CSF) changes could not be excluded in the inhibition of tumor development in CCR5 −/− mice. Our data thus show significant clinical implications of CCR5 disruption. Small several molecules inhibiting CCR5 have already been shown to be safe in clinical trials for use in certain diseases such as HIV (55) . Thus, we believe CCR5 is a cancer target, and molecules for inhibition of CCR5 could be applicable for the treatment of lung cancer. 
